Migraine Clinical Trial
Official title:
Saccadometry in Primary Headache Syndromes
Migraine is one of the commonest neurological disorders, affecting up to 12% of the general
population, but remains relatively under-diagnosed and under-treated. Migraine has a wide
socioeconomic impact and brings a large economic burden; estimates suggest that disability
due to migraine costs > €27 billion per annum across Europe. Despite its prevalence and
impact, migraine pathophysiology is poorly understood. A wider understanding of the
functional changes in this disorder would be beneficial to both diagnosis and treatment.
Saccades are the rapid eye movements we make when moving the eyes to a new object in our
visual field. Reaction time studies have been used to investigate Huntington's disease and
Parkinson's disease with great success. These use saccadic tasks (monitoring eye movements).
Even at rest we make approximately three saccades per second, so a lot of data can quickly be
gathered with non-invasive testing. We hope to understand more of the underlying mechanisms
of migraine by studying reaction time in migraine patients.
Our previous pilot study, with less stringent inclusion and exclusion criteria, looked at
fewer patients (32 migraineurs and 32 controls), and found that migraineurs showed
significantly different saccadic patterns to non-migraineurs.
This study firstly seeks to corroborate the saccadometric findings of our earlier pilot study
in a group of migraineurs, and secondly to explore the specificity of these findings in
migraine by also studying patients with another primary headache syndrome, namely cluster
headache.
Migraine is known to be a dynamic disorder, with previous studies showing longitudinal
changes in the migraine brain. To explore this further we hope to record longitudinally
(Every day for 21 days) in a small subset of migraineurs to identify potential longitudinal
changes in saccadic reaction time. Because of the portability of the equipment this could be
done in the subjects own home if they preferred.
As above ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |